Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans

(2018) Leroy R. A. Lepelaars et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)

(2018) Ramesh Palaparthy et al.   Expert Review of Clinical Immunology

Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database

(2018) Jiyoun Kim et al.   International Journal of Rheumatic Diseases

Use of Infliximab Biosimilar Versus Originator in a Paediatric United Kingdom Inflammatory Bowel Disease Induction Cohort

(2018) Neil Chanchlani et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES

(2018) M. Tee et al.   VALUE IN HEALTH

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)

(2016) Mazin Derzi et al.   ADVANCES IN THERAPY

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

(2015) Ashok Jha et al.   ADVANCES IN THERAPY

Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis

(2015) D. Christophorou et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis

(2014) Siddharth Singh et al.   MAYO CLINIC PROCEEDINGS

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES